Standard Treatment Strategies for FH-III

Standard care for Familial Hyperaldosteronism Type III (FH-III) is a balance between controlling extreme blood pressure and managing a rare genetic condition that often resists standard pills. Because the mutation is in every cell of the adrenal glands, the glands are often enlarged on both sides (bilateral adrenal hyperplasia) and produce aldosterone at levels far higher than the body can handle ^[1][2].

The Medical Management Path

The first line of defense is typically medical management using Mineralocorticoid Receptor Antagonists (MRAs) ^[3]. These drugs do not stop the body from making aldosterone; instead, they sit on the “receivers” (receptors) in your kidneys to block the hormone’s signal ^[4].

• First-line Drugs: Spironolactone is the most common choice due to its potency and low cost ^[3]. If it causes side effects—such as breast tenderness or growth (gynecomastia) in males, or menstrual effects—doctors may switch to eplerenone, which is more specific but sometimes less powerful ^[3][5].
• Titration and Monitoring: An unsuppressed renin is one adjunctive marker that aldosterone is being blocked ^[3][6]. However, dose decisions are not based on renin alone; they also require monitoring blood pressure, potassium, creatinine/eGFR, adverse effects, and adherence. Be aware that MRAs can cause hyperkalemia (high potassium) and renal dysfunction, particularly if there is underlying chronic kidney disease or concomitant ACE inhibitor/ARB therapy, requiring close monitoring after initiation and dose changes.
• Add-on Therapies: If MRAs alone aren’t enough, doctors may add other medications like amiloride (which helps save potassium) or calcium channel blockers ^[7].

Limitations of Medication

For many people with FH-III, medication is only a temporary fix. Because the genetic “leak” is so severe, even high doses of MRAs may fail to control blood pressure or protect the kidneys from damage over time ^[1][8]. In some cases, the medication burden—taking many pills multiple times a day—becomes unacceptable for patients and families ^[1].

The Surgical Path (Bilateral Adrenalectomy)

When medication cannot keep blood pressure safe, target-organ injury occurs, or treatment burden is unacceptable, surgery to remove both adrenal glands (bilateral adrenalectomy) may be considered as an individualized option ^[1][9].

In most other types of primary aldosteronism, surgery involves removing only one gland. In FH-III, however, both glands are overactive. Removing only one rarely provides a cure ^[10].

Outcomes and Life After Surgery

Surgery removes the adrenal source of aldosterone, which often corrects hypokalemia and leads to an improvement in blood pressure (though hypertension may persist) ^[11]. This brings a potential improvement in quality of life, though long-term cardiovascular or renal outcome data for FH-III are sparse ^[12][13]. Surgery also carries irreversible surgical, bleeding, and infection risks.

The Trade-off: Adrenal Insufficiency

It is vital to understand that a bilateral adrenalectomy is not a “cure-all” without consequences. By removing both glands, you are swapping one condition (Primary Aldosteronism) for another (Adrenal Insufficiency) ^[14].

Without adrenal glands, the body can no longer produce cortisol—the hormone that helps you handle stress and illness. This means:

• Lifelong Medication: You must take daily glucocorticoid replacement (like hydrocortisone) and usually mineralocorticoid replacement ^[14].
• Sick Day Rules: During illness, fever, or injury, the dose must be increased (“stress dosing”) to prevent a life-threatening adrenal crisis ^[15].
• Emergency Kits: Patients must carry medical-alert identification and an emergency injectable steroid kit for severe crises ^[15].

Decision Summary Comparison

While surgery is an option for many severe cases, the timing is a personal decision made between the family and a specialized medical team, based on biochemical control, target-organ status, and patient preference ^[16][9].